Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Jianjiao Ni"'
Autor:
Jinmeng Zhang, Jiuang Mao, Dayu Xu, Shanshan Jiang, Tiantian Guo, Yue Zhou, Li Chu, Xi Yang, Xiao Chu, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
Cancer Medicine. 12:6971-6979
Considerable differences of treatment response and pattern of failure may exist between definitive chemoradiation (CRT) treated locally advanced non-small cell lung cancer (LA-NSCLC) patients. The clinical value of additional tyrosine kinase inhibito
Autor:
Shanshan Jiang, Yue Zhou, Liqing Zou, Li Chu, Xiao Chu, Jianjiao Ni, Yida Li, Tiantian Guo, Xi Yang, Zhengfei Zhu
Publikováno v:
Cancer Medicine. 12:4434-4445
Abnormal vascular network of tumor can create a hypoxic microenvironment, and reduce radiotherapy sensitivity. Normalization of tumor vasculature can be a new therapeutic strategy for sensitizing radiotherapy. This study aimed to explore the effect o
Autor:
Zhengfei Zhu, Jianjiao Ni, Xuwei Cai, Shengfa Su, Hongqing Zhuang, Zhenzhou Yang, Ming Chen, Shenglin Ma, Conghua Xie, Yaping Xu, Jiancheng Li, Hong Ge, Anwen Liu, Lujun Zhao, Chuangzhou Rao, Congying Xie, Nan Bi, Zhouguang Hui, Guangying Zhu, Zhiyong Yuan, Jun Wang, Lina Zhao, Wei Zhou, Chai Hong Rim, Arturo Navarro-Martin, Ben G. L. Vanneste, Dirk De Ruysscher, J. Isabelle Choi, Jacek Jassem, Joe Y. Chang, Lucyna Kepka, Lukas Käsmann, Michael T. Milano, Paul Van Houtte, Rafal Suwinski, Alberto Traverso, Hiroshi Doi, Yang-Gun Suh, Georges Noël, Natsuo Tomita, Roman O. Kowalchuk, Terence T. Sio, Baosheng Li, Bing Lu, Xiaolong Fu
Publikováno v:
Translational Lung Cancer Research, 11, 1763-1795. AME Publishing Company
Background: Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has historically served as a palliative modality in metastatic NSCLC, considerable a
Autor:
Xiao, Chu, Yuyin, Xu, Ye, Li, Yue, Zhou, Li, Chu, Xi, Yang, Jianjiao, Ni, Yida, Li, Tiantian, Guo, Zhiqin, Zheng, Qiang, Zheng, Qianlan, Yao, Yuan, Li, Xiaoyan, Zhou, Zhengfei, Zhu
Publikováno v:
Lung Cancer. 169:22-30
Neuroendocrine transformation (NET) is a resistance mechanism for epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). We aimed to elucidate whether NET deve
Autor:
Shanshan Jiang, Jinmeng Zhang, Li Chu, Xiao Chu, Xi Yang, Yida Li, Tiantian Guo, Yue Zhou, Dayu Xu, Jiuang Mao, Zhiqin Zheng, Yulin An, Hua Sun, Huiling Dong, Silai Yu, Ruiting Ye, Jie Hu, Qian Chu, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 180
Purpose: To explore the clinical characteristics, management, and survival outcomes of advanced NSCLC patients treated with PD-1/PD-L1 inhibitors who presented with an atypical response (AR). Methods: A total of 926 PD-1/PD-L1-inhibitor-treated patie
Autor:
Yuan Li, Zhengfei Zhu, Yang Zhao, Wanqin Zeng, Xiao Chu, Jianjiao Ni, Tiantian Guo, Wen Yu, Liqing Zou, Shengping Wang, Q. Liu, Yue Zhou, Yida Li, Luxi Ye, Ya Zeng, Li Chu, Shuyan Li, Xi Yang, Fan Yu
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:804-815
Purpose As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant
Autor:
Ya Zeng, Shuyan Li, Yida Li, Fei Liang, Xiao Chu, Yang Zhao, Bo Wang, Liqing Zou, Shengping Wang, Q. Liu, Jinghan Qu, Li Chu, Fan Yu, Zhengfei Zhu, Yue Zhou, Xi Yang, Tiantian Guo, Jianjiao Ni, Luxi Ye
Publikováno v:
Lung Cancer. 150:178-185
Objectives Central nervous system (CNS) metastases are common complications in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs). However, for patients without baseli
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 307
Introduction: Brain is a major site of metastasis for lung cancer, and effective therapy for developed brain metastasis (BM) is limited. Prophylactic cranial irradiation (PCI) has been shown to reduce BM rate and improve survival in small cell lung c
Autor:
Ya Zeng, Xi Su, Yang Zhao, Yue Zhou, Tiantian Guo, Xiao Chu, Li Chu, Xi Yang, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
Therapeutic Advances in Medical Oncology. 15:175883592311699
Objectives: To explore the rationale and value of consolidative cranial local therapy (CLT) in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). Methods: EGFR-mutant NSCLC patients
Publikováno v:
Transl Lung Cancer Res
Significant recent advances have occurred in the use of radiation therapy for locally advanced non-small cell lung cancer (LA-NSCLC). In fact, the past few decades have seen both therapeutic gains and setbacks in the evolution of radiotherapy for LA-